MedTrace Logo

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

NCT02189174 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-12-03

No results posted yet for this study

Summary

To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

CLR457

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-07
Primary Completion
2015-11-12
Completion
2015-11-12

Countries

  • United States
  • Canada
  • Japan
  • Singapore
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189174 on ClinicalTrials.gov